ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness

Next-generation anti-CD19 CAR-T, Anbal-cel (CRC01), approval highlights Korean innovation HOPEWELL, N.J., May. 11, 2026 /PRNewswire/ -- Given the accelerating global momentum in CAR-T and gene therapies, ProBio Inc. and Curocell have achieved a significant milestone with the BLA...